Liquidia Corporation (NASDAQ:LQDA) Receives $38.56 Consensus PT from Brokerages

by · The Cerbat Gem

Shares of Liquidia Corporation (NASDAQ:LQDA – Get Free Report) have received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $38.5556.

LQDA has been the topic of several recent research reports. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price target on shares of Liquidia in a report on Monday, November 3rd. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Needham & Company LLC increased their target price on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Raymond James Financial reissued a “strong-buy” rating and issued a $47.00 price target on shares of Liquidia in a report on Tuesday, November 4th. Finally, BTIG Research restated a “buy” rating and issued a $49.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th.

Read Our Latest Research Report on Liquidia

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 20,261 shares of the firm’s stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $23.41, for a total transaction of $474,310.01. Following the sale, the chief executive officer owned 1,032,973 shares in the company, valued at approximately $24,181,897.93. This trade represents a 1.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Raman Singh sold 45,524 shares of Liquidia stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $25.81, for a total transaction of $1,174,974.44. Following the completion of the sale, the director directly owned 31,255 shares of the company’s stock, valued at $806,691.55. The trade was a 59.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 215,168 shares of company stock worth $5,675,425 in the last 90 days. 26.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Cetera Investment Advisers raised its holdings in Liquidia by 34.4% in the first quarter. Cetera Investment Advisers now owns 41,999 shares of the company’s stock valued at $619,000 after acquiring an additional 10,756 shares in the last quarter. CenterBook Partners LP acquired a new position in shares of Liquidia in the 1st quarter valued at about $1,786,000. Aigen Investment Management LP acquired a new position in Liquidia in the first quarter valued at approximately $151,000. Nuveen LLC bought a new position in Liquidia during the 1st quarter worth $2,642,000. Finally, Kovitz Investment Group Partners LLC bought a new position in shares of Liquidia during the first quarter worth about $384,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Trading Up 0.5%

Shares of LQDA stock opened at $33.92 on Tuesday. Liquidia has a fifty-two week low of $10.37 and a fifty-two week high of $34.08. The stock has a market cap of $2.95 billion, a P/E ratio of -23.56 and a beta of 0.48. The business has a fifty day simple moving average of $26.04 and a 200-day simple moving average of $21.73. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19.

Liquidia (NASDAQ:LQDA – Get Free Report) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. Liquidia’s quarterly revenue was up 1106.7% compared to the same quarter last year. On average, analysts forecast that Liquidia will post -1.51 earnings per share for the current fiscal year.

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Read More